Celator begins Phase III study of injectable AML drug

12/28/2012 | Pharmaceutical Business Review Online

Celator Pharmaceuticals has started enrolling patients in a late-stage trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with high-risk acute myeloid leukemia. The multicenter trial will be carried out in the U.S. and Canada. "The initiation of this study is an important milestone for CPX-351 and for Celator. We hope the data it provides will allow us to seek regulatory approval for CPX-351," Celator CEO Scott Jackson said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA